×
phase Ib/II study of ivosidenib with venetoclax plus /- azacitidine in IDH1-mutated myeloid malignancies.
Lachowiez CA., Borthakur G., Loghavi S., Zeng Z., Kadia TM., Masarova L., Takahashi K., Tippett GD., Smith S., Garcia JS., Bose P., Jabbour E., Ravandi F., Daver NG., Garcia-Manero G., Stoilova B., Vyas P., Kantarjian HM., Konopleva M., Dinardo CD.
DOI
10.1200/JCO.2021.39.15_suppl.7012
Type
Conference paper
Publication Date
2021-01-01T00:00:00+00:00
Volume
39